CIK 0002012593
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Rapport Therapeutics, Inc.
Sign in to watch- Ticker
- RAPP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 880724208
- Phone
- +1 857-321-8020
- Business address
- 99 HIGH STREET, SUITE 2100, BOSTON, MA, 02110
- Former names
- Rapport Therapeutics, Inc.
- Open-market buys, last 90 days
- $22,023,904
- in 7 filings
- Open-market sales, last 90 days
- $4,470,180
- in 7 filings, $4.5M under 10b5-1 plans
Net +$17,553,724. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-30 | Gault Cheryl Chief Operating Officer | Sale 10b5-1 | −7,161 | $28.04 | $201K | 162,753 |
| 2026-03-30 | Gault Cheryl Chief Operating Officer | Sale 10b5-1 | −2,839 | $28.55 | $81K | 159,914 |
| 2026-03-25 | Yeleswaram Krishnaswamy Chief Development Officer | Sale 10b5-1 | −10,115 | $29.99 | $303K | 286,876 |
| 2026-03-05 | Gault Cheryl Chief Operating Officer | Sale | −2,014 | $28.93 | $58K | 169,914 |
| 2026-02-18 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −3,552 | $29.05 | $103K | 558,528 |
| 2026-02-18 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −2,281 | $29.80 | $68K | 556,247 |
| 2026-02-18 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −2,983 | $29.04 | $87K | 22,829 |
| 2026-02-18 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −2,100 | $29.80 | $63K | 20,729 |
| 2026-02-17 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −900 | $28.02 | $25K | 394,675 |
| 2026-02-17 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −5,400 | $28.95 | $156K | 389,275 |
| 2026-02-17 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −2,200 | $29.59 | $65K | 387,075 |
| 2026-01-20 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −5,833 | $26.12 | $152K | 562,080 |
| 2026-01-20 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −5,083 | $26.11 | $133K | 25,812 |
| 2026-01-15 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −8,300 | $26.83 | $223K | 395,775 |
| 2026-01-15 | Bredt David Chief Scientific Officer | Sale 10b5-1 | −200 | $27.40 | $5K | 395,575 |
| 2025-12-31 | Bredt David Chief Scientific Officer | Sale | −6,567 | $30.05 | $197K | 404,075 |
| 2025-12-31 | Yeleswaram Krishnaswamy Chief Development Officer | Sale | −2,840 | $30.05 | $85K | 296,991 |
| 2025-12-17 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −2,441 | $28.84 | $70K | 571,305 |
| 2025-12-17 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −2,792 | $30.04 | $84K | 568,513 |
| 2025-12-17 | Ceesay Abraham Chief Executive Officer | Sale 10b5-1 | −600 | $31.04 | $19K | 567,913 |
Page 3 of 5 · 92 trades